Home > Press Releases > Microbiome Therapeutics Market

Microbiome Therapeutics Market Likely Reach ~USD 15 billion by 2035

Report Code: HC-6271  |  Published in: Apr 2026, By MarketGenics  |  Number of pages: 295
Get PDF
Buy

Global Microbiome Therapeutics Market Forecast 2035:

According to the report, the global microbiome therapeutics market is likely to grow from USD 1 Billion in 2025 to USD 14.7 Billion in 2035 at a highest CAGR of 31.2% during the time period. Globally, there is an accelerated growth in the microbiome therapeutics market fueled by a rise in cases of gastrointestinal, metabolic and immune diseases; greater clinical validation of the efficacy of therapeutics targeting the gut through the microbiome; and increased investment into next-generation living biotherapeutics.

There has also been a significant push from companies/research institutions to develop standardized consortia of microbes as well as oral delivery systems to enhance treatment efficacy, conform to patient compliance and enhance safety. This activity has been enabled by the increasing support from government-backed initiatives designed to generate healthcare solutions (execution and commercial applications) and a commitment from regulatory bodies (particularly in North America and Europe) to facilitate and progress the clinical trial/approval process.

Additionally, developments within multi-omics technology, artificial intelligence (AI) driven microbial characterization and precision medicine are facilitating personalized therapies, while partnerships between biotech and pharmaceutical companies are enabling enhanced access; e.g. In 2025, Vedanta Biosciences announced successful Phase II data regarding its microbiome product for the treatment of ulcerative colitis therefore confirming the clinical momentum behind the microbiome's potential as a viable therapeutical.                                                                                                                                                     

Key Driver, Restraint, and Growth Opportunity Shaping the Global Microbiome Therapeutics Market

The global microbiome therapeutics market experiences growth because medical facilities begin to use microbiome-based treatments which utilize standardized microbial consortia to treat gastrointestinal and metabolic diseases through gut health restoration. For instance, Rebiotix (Ferring Pharmaceuticals) progressed its oral microbiome treatment for recurrent Clostridioides difficile infection in 2025 while Seres Therapeutics, Inc. shared new information about its development pipeline which makes its treatments more accessible for patients.

The main obstacle for live biotherapeutics is to establish reproducible and stable products because microbial composition and product formulation and manufacturing conditions create challenges which make it difficult to scale operations and raise expenses especially for products that contain multiple strains of bacteria. The manufacturing difficulties during late-stage trials which led to multiple small developers postponing their product launches demonstrated this point.

Microbiome therapeutics for oncology and immunology present a major opportunity because changing gut microbiome patterns improves patient results with immunotherapy treatments. Vedanta Biosciences released positive first clinical findings in 2024 which showed that cancer patients exhibited better immune function, while biotech firms and major cancer centers formed partnerships to investigate microbiome-immuno oncology combinations, which showed research potential outside traditional gastrointestinal applications.

Expansion of Global Microbiome Therapeutics Market

Clinical Advances, Precision Medicine, and Strategic Collaborations Driving the Global Microbiome Therapeutics Market Expansion

  • The global microbiome therapeutics market is experiencing rapid growth due to the basic science of the human microbiome leading to new opportunities in clinical application and precision medicine. The growth of the market is also due to the increase in funding for research and development of targeted therapies to modify the microbial community and treat gastrointestinal, metabolic and immune-related diseases, as well as to develop new use of therapies to treat different disorders other than what they are currently indicated for.
  • The use of multi-omics, genomics, and advanced bioinformatics is enabling personalized medicine, allowing for individualized treatment options tailored specifically to each person’s unique microbiota composition, thus improving treatment effectiveness and patient outcomes. The increase in collaboration between innovator biotech enterprises and established pharmaceutical companies is accelerating the clinical validation, regulatory approval, and commercialization of microbiome therapies.
  • For example, EnteroBiotix Limited's recent positive Phase 2 results from its oral microbiome therapy for treating IBS-C/IBS-D patients shows an increasing trend towards the clinical application of precision medicine using the human microbiome. The increase in venture capital investments along with the establishment of partnerships with research institutions around the world will provide additional support for the diversification of the development pipeline and the expansion of these therapies into a variety of diseases.

Regional Analysis of Global Microbiome Therapeutics Market

  • North America exhibits the greatest need for microbiome therapeutics because the region possesses advanced biotechnology facilities and experiences high rates of gastrointestinal and metabolic diseases and benefits from clear regulatory processes which enable speedier drug development. The CDC reports that more than 223, 900 adults in the United States experience recurrent Clostridioides difficile infections which leads to increased need for fecal microbiota transplantation FMT and other microbiome-based treatments.
  • The market leadership of the region receives additional support from strategic alliances which include Seres Therapeutics partnerships with Nestlé Health Science and Vedanta Biosciences clinical expansion initiatives and the existence of effective reimbursement policies for microbiome treatment solutions.
  • The Asia Pacific region experiences the fastest growth because people become more aware of gut health while healthcare facilities expand and governments establish microbiome research initiatives. The Precision Medicine Initiative in China supports microbiome clinical trials while Indian institutions partner with biotech startups to advance microbiome therapy research.
  • The combination of local companies like MaaT Pharma expanding into new markets and their partnerships with worldwide pharmaceutical firms together with rising venture capital funding is propelling the Asia Pacific microbiome therapeutics market to achieve double-digit growth while clinical adoption rates increase.

Prominent players operating in global microbiome therapeutics market include prominent companies such as 4D pharma plc, AOBiome Therapeutics, Inc., Assembly Biosciences, Inc., Axial Therapeutics, Inc., BiomX Inc., EnteroBiotix Ltd., Enterome SA, Ferring Pharmaceuticals A/S, Finch Therapeutics Group, Inc., Intralytix, Inc., Locus Biosciences, Inc., MaaT Pharma SA, Microbiotica Ltd., Pendulum Therapeutics, Inc., Rebiotix Inc., Second Genome, Inc., Seres Therapeutics, Inc., Siolta Therapeutics, Inc., Synlogic, Inc., Vedanta Biosciences, Inc., along with several other key players.

The global microbiome therapeutics market has been segmented as follows:

Global Microbiome Therapeutics Market Analysis, by Product Type

  • Live Biotherapeutic Products (LBPs)
  • Fecal Microbiota Transplantation (FMT)
  • Engineered Microbial Consortia
  • Probiotics
  • Prebiotics
  • Postbiotics
  • Synbiotics
  • Others

Global Microbiome Therapeutics Market Analysis, by Therapy Type

  • Additive Therapies
  • Subtractive Therapies
  • Modulatory Therapies
  • Microbiome Drug-Based Therapies
  • Bacteriophage-Based Therapies
  • Others

Global Microbiome Therapeutics Market Analysis, by Route of Administration

  • Oral
  • Rectal (Enema/Colonoscopy Delivery)
  • Injectable
  • Topical

Global Microbiome Therapeutics Market Analysis, by Disease Area

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Infectious Diseases
  • Oncology
  • Immune & Autoimmune Disorders
  • Neurological Disorders
  • Dermatological Disorders
  • Others

Global Microbiome Therapeutics Market Analysis, by Mechanism of Action

  • Microbiome Restoration
  • Immune Modulation
  • Metabolic Modulation
  • Pathogen Suppression
  • Gut-Brain Axis Modulation
  • Others

Global Microbiome Therapeutics Market Analysis, by Application

  • Clostridium difficile (C. diff) Infection
  • Inflammatory Bowel Disease (IBD)
  • Crohn’s Disease
  • Metabolic Disorders (Diabetes, Obesity)
  • Oncology
  • Autoimmune Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Others

Global Microbiome Therapeutics Market Analysis, by End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Specialty Centers
  • Homecare Settings
  • Others

Global Microbiome Therapeutics Market Analysis, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies / E-commerce
  • Specialty Pharmacies
  • Others

Global Microbiome Therapeutics Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Microbiome Therapeutics Market Outlook
      • 2.1.1. Microbiome Therapeutics Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Information Technology & Media Ecosystem Overview, 2025
      • 3.1.1. Information Technology & Media Industry Analysis
      • 3.1.2. Key Trends for Information Technology & Media Industry
      • 3.1.3. Regional Distribution for Information Technology & Media Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising prevalence of gastrointestinal and metabolic disorders increasing therapy demand.
        • 4.1.1.2. Growing clinical validation and regulatory support for microbiome-based therapies.
        • 4.1.1.3. Advancements in precision medicine, multi-omics, and AI-enabled microbial analysis.
      • 4.1.2. Restraints
        • 4.1.2.1. Complex manufacturing processes and high production costs of live biotherapeutics.
        • 4.1.2.2. Lack of standardized protocols for microbial composition and quality control.
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Microbiome Therapeutics Market Demand
      • 4.7.1. Historical Market Size – Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size – Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Microbiome Therapeutics Market Analysis, by Product Type
    • 6.1. Key Segment Analysis
    • 6.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Product Type, 2021-2035
      • 6.2.1. Live Biotherapeutic Products (LBPs)
      • 6.2.2. Fecal Microbiota Transplantation (FMT)
      • 6.2.3. Engineered Microbial Consortia
      • 6.2.4. Probiotics
      • 6.2.5. Prebiotics
      • 6.2.6. Postbiotics
      • 6.2.7. Synbiotics
      • 6.2.8. Others
  • 7. OthersGlobal Microbiome Therapeutics Market Analysis, by Therapy Type
    • 7.1. Key Segment Analysis
    • 7.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapy Type, 2021-2035
      • 7.2.1. Additive Therapies
      • 7.2.2. Subtractive Therapies
      • 7.2.3. Modulatory Therapies
      • 7.2.4. Microbiome Drug-Based Therapies
      • 7.2.5. Bacteriophage-Based Therapies
      • 7.2.6. Others
  • 8. Global Microbiome Therapeutics Market Analysis, by Route of Administration
    • 8.1. Key Segment Analysis
    • 8.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
      • 8.2.1. Oral
      • 8.2.2. Rectal (Enema/Colonoscopy Delivery)
      • 8.2.3. Injectable
      • 8.2.4. Topical
  • 9. Global Microbiome Therapeutics Market Analysis, by Disease Area
    • 9.1. Key Segment Analysis
    • 9.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Disease Area, 2021-2035
      • 9.2.1. Gastrointestinal Disorders
      • 9.2.2. Metabolic Disorders
      • 9.2.3. Infectious Diseases
      • 9.2.4. Oncology
      • 9.2.5. Immune & Autoimmune Disorders
      • 9.2.6. Neurological Disorders
      • 9.2.7. Dermatological Disorders
      • 9.2.8. Others
  • 10. Global Microbiome Therapeutics Market Analysis, by Mechanism of Action
    • 10.1. Key Segment Analysis
    • 10.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Mechanism of Action, 2021-2035
      • 10.2.1. Microbiome Restoration
      • 10.2.2. Immune Modulation
      • 10.2.3. Metabolic Modulation
      • 10.2.4. Pathogen Suppression
      • 10.2.5. Gut-Brain Axis Modulation
      • 10.2.6. Others
  • 11. Global Microbiome Therapeutics Market Analysis, by Application
    • 11.1. Key Segment Analysis
    • 11.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
      • 11.2.1. Clostridium difficile (C. diff) Infection
      • 11.2.2. Inflammatory Bowel Disease (IBD)
      • 11.2.3. Crohn’s Disease
      • 11.2.4. Metabolic Disorders (Diabetes, Obesity)
      • 11.2.5. Oncology
      • 11.2.6. Autoimmune Disorders
      • 11.2.7. Neurological Disorders
      • 11.2.8. Infectious Diseases
      • 11.2.9. Others
  • 12. Global Microbiome Therapeutics Market Analysis, by End User
    • 12.1. Key Segment Analysis
    • 12.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 12.2.1. Hospitals & Clinics
      • 12.2.2. Pharmaceutical & Biotechnology Companies
      • 12.2.3. Research & Academic Institutes
      • 12.2.4. Specialty Centers
      • 12.2.5. Homecare Settings
      • 12.2.6. Others
  • 13. Global Microbiome Therapeutics Market Analysis and Forecasts, by Distribution Channel
    • 13.1. Key Findings
    • 13.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Distribution Channel, 2021-2035
      • 13.2.1. Hospital Pharmacies
      • 13.2.2. Retail Pharmacies
      • 13.2.3. Drug Stores
      • 13.2.4. Online Pharmacies / E-commerce
      • 13.2.5. Specialty Pharmacies
      • 13.2.6. Others
  • 14. Global Microbiome Therapeutics Market Analysis and Forecasts, by Region
    • 14.1. Key Findings
    • 14.2. Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 14.2.1. North America
      • 14.2.2. Europe
      • 14.2.3. Asia Pacific
      • 14.2.4. Middle East
      • 14.2.5. Africa
      • 14.2.6. South America
  • 15. North America Microbiome Therapeutics Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. North America Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Component
      • 15.3.2. Therapy Type
      • 15.3.3. Route of Administration
      • 15.3.4. Disease Area
      • 15.3.5. Mechanism of Action
      • 15.3.6. Application
      • 15.3.7. End User
      • 15.3.8. Distribution Channel
      • 15.3.9. Country
        • 15.3.9.1. USA
        • 15.3.9.2. Canada
        • 15.3.9.3. Mexico
    • 15.4. USA Microbiome Therapeutics Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Component
      • 15.4.3. Therapy Type
      • 15.4.4. Route of Administration
      • 15.4.5. Disease Area
      • 15.4.6. Mechanism of Action
      • 15.4.7. Application
      • 15.4.8. End User
      • 15.4.9. Distribution Channel
    • 15.5. Canada Microbiome Therapeutics Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Component
      • 15.5.3. Therapy Type
      • 15.5.4. Route of Administration
      • 15.5.5. Disease Area
      • 15.5.6. Mechanism of Action
      • 15.5.7. Application
      • 15.5.8. End User
      • 15.5.9. Distribution Channel
    • 15.6. Mexico Microbiome Therapeutics Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Component
      • 15.6.3. Therapy Type
      • 15.6.4. Route of Administration
      • 15.6.5. Disease Area
      • 15.6.6. Mechanism of Action
      • 15.6.7. Application
      • 15.6.8. End User
      • 15.6.9. Distribution Channel
  • 16. Europe Microbiome Therapeutics Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Europe Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Component
      • 16.3.2. Therapy Type
      • 16.3.3. Route of Administration
      • 16.3.4. Disease Area
      • 16.3.5. Mechanism of Action
      • 16.3.6. Application
      • 16.3.7. End User
      • 16.3.8. Distribution Channel
      • 16.3.9. Country
        • 16.3.9.1. Germany
        • 16.3.9.2. United Kingdom
        • 16.3.9.3. France
        • 16.3.9.4. Italy
        • 16.3.9.5. Spain
        • 16.3.9.6. Netherlands
        • 16.3.9.7. Nordic Countries
        • 16.3.9.8. Poland
        • 16.3.9.9. Russia & CIS
        • 16.3.9.10. Rest of Europe
    • 16.4. Germany Microbiome Therapeutics Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Component
      • 16.4.3. Therapy Type
      • 16.4.4. Route of Administration
      • 16.4.5. Disease Area
      • 16.4.6. Mechanism of Action
      • 16.4.7. Application
      • 16.4.8. End User
      • 16.4.9. Distribution Channel
    • 16.5. United Kingdom Microbiome Therapeutics Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Component
      • 16.5.3. Therapy Type
      • 16.5.4. Route of Administration
      • 16.5.5. Disease Area
      • 16.5.6. Mechanism of Action
      • 16.5.7. Application
      • 16.5.8. End User
      • 16.5.9. Distribution Channel
    • 16.6. France Microbiome Therapeutics Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Component
      • 16.6.3. Therapy Type
      • 16.6.4. Route of Administration
      • 16.6.5. Disease Area
      • 16.6.6. Mechanism of Action
      • 16.6.7. Application
      • 16.6.8. End User
      • 16.6.9. Distribution Channel
    • 16.7. Italy Microbiome Therapeutics Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Component
      • 16.7.3. Therapy Type
      • 16.7.4. Route of Administration
      • 16.7.5. Disease Area
      • 16.7.6. Mechanism of Action
      • 16.7.7. Application
      • 16.7.8. End User
      • 16.7.9. Distribution Channel
    • 16.8. Spain Microbiome Therapeutics Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Component
      • 16.8.3. Therapy Type
      • 16.8.4. Route of Administration
      • 16.8.5. Disease Area
      • 16.8.6. Mechanism of Action
      • 16.8.7. Application
      • 16.8.8. End User
      • 16.8.9. Distribution Channel
    • 16.9. Netherlands Microbiome Therapeutics Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Component
      • 16.9.3. Therapy Type
      • 16.9.4. Route of Administration
      • 16.9.5. Disease Area
      • 16.9.6. Mechanism of Action
      • 16.9.7. Application
      • 16.9.8. End User
      • 16.9.9. Distribution Channel
    • 16.10. Nordic Countries Microbiome Therapeutics Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Component
      • 16.10.3. Therapy Type
      • 16.10.4. Route of Administration
      • 16.10.5. Disease Area
      • 16.10.6. Mechanism of Action
      • 16.10.7. Application
      • 16.10.8. End User
      • 16.10.9. Distribution Channel
    • 16.11. Poland Microbiome Therapeutics Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Component
      • 16.11.3. Therapy Type
      • 16.11.4. Route of Administration
      • 16.11.5. Disease Area
      • 16.11.6. Mechanism of Action
      • 16.11.7. Application
      • 16.11.8. End User
      • 16.11.9. Distribution Channel
    • 16.12. Russia & CIS Microbiome Therapeutics Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Component
      • 16.12.3. Therapy Type
      • 16.12.4. Route of Administration
      • 16.12.5. Disease Area
      • 16.12.6. Mechanism of Action
      • 16.12.7. Application
      • 16.12.8. End User
      • 16.12.9. Distribution Channel
    • 16.13. Rest of Europe Microbiome Therapeutics Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Component
      • 16.13.3. Therapy Type
      • 16.13.4. Route of Administration
      • 16.13.5. Disease Area
      • 16.13.6. Mechanism of Action
      • 16.13.7. Application
      • 16.13.8. End User
      • 16.13.9. Distribution Channel
  • 17. Asia Pacific Microbiome Therapeutics Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Asia Pacific Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Component
      • 17.3.2. Therapy Type
      • 17.3.3. Route of Administration
      • 17.3.4. Disease Area
      • 17.3.5. Mechanism of Action
      • 17.3.6. Application
      • 17.3.7. End User
      • 17.3.8. Distribution Channel
      • 17.3.9. Country
        • 17.3.9.1. China
        • 17.3.9.2. India
        • 17.3.9.3. Japan
        • 17.3.9.4. South Korea
        • 17.3.9.5. Australia and New Zealand
        • 17.3.9.6. Indonesia
        • 17.3.9.7. Malaysia
        • 17.3.9.8. Thailand
        • 17.3.9.9. Vietnam
        • 17.3.9.10. Rest of Asia Pacific
    • 17.4. China Microbiome Therapeutics Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Component
      • 17.4.3. Therapy Type
      • 17.4.4. Route of Administration
      • 17.4.5. Disease Area
      • 17.4.6. Mechanism of Action
      • 17.4.7. Application
      • 17.4.8. End User
      • 17.4.9. Distribution Channel
    • 17.5. India Microbiome Therapeutics Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Component
      • 17.5.3. Therapy Type
      • 17.5.4. Route of Administration
      • 17.5.5. Disease Area
      • 17.5.6. Mechanism of Action
      • 17.5.7. Application
      • 17.5.8. End User
      • 17.5.9. Distribution Channel
    • 17.6. Japan Microbiome Therapeutics Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Component
      • 17.6.3. Therapy Type
      • 17.6.4. Route of Administration
      • 17.6.5. Disease Area
      • 17.6.6. Mechanism of Action
      • 17.6.7. Application
      • 17.6.8. End User
      • 17.6.9. Distribution Channel
    • 17.7. South Korea Microbiome Therapeutics Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Component
      • 17.7.3. Therapy Type
      • 17.7.4. Route of Administration
      • 17.7.5. Disease Area
      • 17.7.6. Mechanism of Action
      • 17.7.7. Application
      • 17.7.8. End User
      • 17.7.9. Distribution Channel
    • 17.8. Australia and New Zealand Microbiome Therapeutics Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Component
      • 17.8.3. Therapy Type
      • 17.8.4. Route of Administration
      • 17.8.5. Disease Area
      • 17.8.6. Mechanism of Action
      • 17.8.7. Application
      • 17.8.8. End User
      • 17.8.9. Distribution Channel
    • 17.9. Indonesia Microbiome Therapeutics Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Component
      • 17.9.3. Therapy Type
      • 17.9.4. Route of Administration
      • 17.9.5. Disease Area
      • 17.9.6. Mechanism of Action
      • 17.9.7. Application
      • 17.9.8. End User
      • 17.9.9. Distribution Channel
    • 17.10. Malaysia Microbiome Therapeutics Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Component
      • 17.10.3. Therapy Type
      • 17.10.4. Route of Administration
      • 17.10.5. Disease Area
      • 17.10.6. Mechanism of Action
      • 17.10.7. Application
      • 17.10.8. End User
      • 17.10.9. Distribution Channel
    • 17.11. Thailand Microbiome Therapeutics Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Component
      • 17.11.3. Therapy Type
      • 17.11.4. Route of Administration
      • 17.11.5. Disease Area
      • 17.11.6. Mechanism of Action
      • 17.11.7. Application
      • 17.11.8. End User
      • 17.11.9. Distribution Channel
    • 17.12. Vietnam Microbiome Therapeutics Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Component
      • 17.12.3. Therapy Type
      • 17.12.4. Route of Administration
      • 17.12.5. Disease Area
      • 17.12.6. Mechanism of Action
      • 17.12.7. Application
      • 17.12.8. End User
      • 17.12.9. Distribution Channel
    • 17.13. Rest of Asia Pacific Microbiome Therapeutics Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Component
      • 17.13.3. Therapy Type
      • 17.13.4. Route of Administration
      • 17.13.5. Disease Area
      • 17.13.6. Mechanism of Action
      • 17.13.7. Application
      • 17.13.8. End User
      • 17.13.9. Distribution Channel
  • 18. Middle East Microbiome Therapeutics Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Middle East Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Component
      • 18.3.2. Therapy Type
      • 18.3.3. Route of Administration
      • 18.3.4. Disease Area
      • 18.3.5. Mechanism of Action
      • 18.3.6. Application
      • 18.3.7. End User
      • 18.3.8. Distribution Channel
      • 18.3.9. Country
        • 18.3.9.1. Turkey
        • 18.3.9.2. UAE
        • 18.3.9.3. Saudi Arabia
        • 18.3.9.4. Israel
        • 18.3.9.5. Rest of Middle East
    • 18.4. Turkey Microbiome Therapeutics Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Component
      • 18.4.3. Therapy Type
      • 18.4.4. Route of Administration
      • 18.4.5. Disease Area
      • 18.4.6. Mechanism of Action
      • 18.4.7. Application
      • 18.4.8. End User
      • 18.4.9. Distribution Channel
    • 18.5. UAE Microbiome Therapeutics Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Component
      • 18.5.3. Therapy Type
      • 18.5.4. Route of Administration
      • 18.5.5. Disease Area
      • 18.5.6. Mechanism of Action
      • 18.5.7. Application
      • 18.5.8. End User
      • 18.5.9. Distribution Channel
    • 18.6. Saudi Arabia Microbiome Therapeutics Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Component
      • 18.6.3. Therapy Type
      • 18.6.4. Route of Administration
      • 18.6.5. Disease Area
      • 18.6.6. Mechanism of Action
      • 18.6.7. Application
      • 18.6.8. End User
      • 18.6.9. Distribution Channel
    • 18.7. Israel Microbiome Therapeutics Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Component
      • 18.7.3. Therapy Type
      • 18.7.4. Route of Administration
      • 18.7.5. Disease Area
      • 18.7.6. Mechanism of Action
      • 18.7.7. Application
      • 18.7.8. End User
      • 18.7.9. Distribution Channel
    • 18.8. Rest of Middle East Microbiome Therapeutics Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Component
      • 18.8.3. Therapy Type
      • 18.8.4. Route of Administration
      • 18.8.5. Disease Area
      • 18.8.6. Mechanism of Action
      • 18.8.7. Application
      • 18.8.8. End User
      • 18.8.9. Distribution Channel
  • 19. Africa Microbiome Therapeutics Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Africa Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Component
      • 19.3.2. Therapy Type
      • 19.3.3. Route of Administration
      • 19.3.4. Disease Area
      • 19.3.5. Mechanism of Action
      • 19.3.6. Application
      • 19.3.7. End User
      • 19.3.8. Distribution Channel
      • 19.3.9. Country
        • 19.3.9.1. South Africa
        • 19.3.9.2. Egypt
        • 19.3.9.3. Nigeria
        • 19.3.9.4. Algeria
        • 19.3.9.5. Rest of Africa
    • 19.4. South Africa Microbiome Therapeutics Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Component
      • 19.4.3. Therapy Type
      • 19.4.4. Route of Administration
      • 19.4.5. Disease Area
      • 19.4.6. Mechanism of Action
      • 19.4.7. Application
      • 19.4.8. End User
      • 19.4.9. Distribution Channel
    • 19.5. Egypt Microbiome Therapeutics Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Component
      • 19.5.3. Therapy Type
      • 19.5.4. Route of Administration
      • 19.5.5. Disease Area
      • 19.5.6. Mechanism of Action
      • 19.5.7. Application
      • 19.5.8. End User
      • 19.5.9. Distribution Channel
    • 19.6. Nigeria Microbiome Therapeutics Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Component
      • 19.6.3. Therapy Type
      • 19.6.4. Route of Administration
      • 19.6.5. Disease Area
      • 19.6.6. Mechanism of Action
      • 19.6.7. Application
      • 19.6.8. End User
      • 19.6.9. Distribution Channel
    • 19.7. Algeria Microbiome Therapeutics Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Component
      • 19.7.3. Therapy Type
      • 19.7.4. Route of Administration
      • 19.7.5. Disease Area
      • 19.7.6. Mechanism of Action
      • 19.7.7. Application
      • 19.7.8. End User
      • 19.7.9. Distribution Channel
    • 19.8. Rest of Africa Microbiome Therapeutics Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Component
      • 19.8.3. Therapy Type
      • 19.8.4. Route of Administration
      • 19.8.5. Disease Area
      • 19.8.6. Mechanism of Action
      • 19.8.7. Application
      • 19.8.8. End User
      • 19.8.9. Distribution Channel
  • 20. South America Microbiome Therapeutics Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. South America Microbiome Therapeutics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Component
      • 20.3.2. Therapy Type
      • 20.3.3. Route of Administration
      • 20.3.4. Disease Area
      • 20.3.5. Mechanism of Action
      • 20.3.6. Application
      • 20.3.7. End User
      • 20.3.8. Distribution Channel
      • 20.3.9. Country
        • 20.3.9.1. Brazil
        • 20.3.9.2. Argentina
        • 20.3.9.3. Rest of South America
    • 20.4. Brazil Microbiome Therapeutics Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Component
      • 20.4.3. Therapy Type
      • 20.4.4. Route of Administration
      • 20.4.5. Disease Area
      • 20.4.6. Mechanism of Action
      • 20.4.7. Application
      • 20.4.8. End User
      • 20.4.9. Distribution Channel
    • 20.5. Argentina Microbiome Therapeutics Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Component
      • 20.5.3. Therapy Type
      • 20.5.4. Route of Administration
      • 20.5.5. Disease Area
      • 20.5.6. Mechanism of Action
      • 20.5.7. Application
      • 20.5.8. End User
      • 20.5.9. Distribution Channel
    • 20.6. Rest of South America Microbiome Therapeutics Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Component
      • 20.6.3. Therapy Type
      • 20.6.4. Route of Administration
      • 20.6.5. Disease Area
      • 20.6.6. Mechanism of Action
      • 20.6.7. Application
      • 20.6.8. End User
      • 20.6.9. Distribution Channel
  • 21. Key Players/ Company Profile
    • 21.1. 4D pharma plc
      • 21.1.1. Company Details/ Overview
      • 21.1.2. Company Financials
      • 21.1.3. Key Customers and Competitors
      • 21.1.4. Business/ Industry Portfolio
      • 21.1.5. Product Portfolio/ Specification Details
      • 21.1.6. Pricing Data
      • 21.1.7. Strategic Overview
      • 21.1.8. Recent Developments
    • 21.2. AOBiome Therapeutics, Inc.
    • 21.3. Assembly Biosciences, Inc.
    • 21.4. Axial Therapeutics, Inc.
    • 21.5. BiomX Inc.
    • 21.6. EnteroBiotix Ltd.
    • 21.7. Enterome SA
    • 21.8. Ferring Pharmaceuticals A/S
    • 21.9. Finch Therapeutics Group, Inc.
    • 21.10. Intralytix, Inc.
    • 21.11. Locus Biosciences, Inc.
    • 21.12. MaaT Pharma SA
    • 21.13. Microbiotica Ltd.
    • 21.14. Pendulum Therapeutics, Inc.
    • 21.15. Rebiotix Inc.
    • 21.16. Second Genome, Inc.
    • 21.17. Seres Therapeutics, Inc.
    • 21.18. Siolta Therapeutics, Inc.
    • 21.19. Synlogic, Inc.
    • 21.20. Vedanta Biosciences, Inc.
    • 21.21. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation